evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Immune checkpoint inhibitors vs any first‐line chemotherapy

Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).

1 finding from 1 review

Immune checkpoint inhibitors vs any second‐line chemotherapy

Time to progression · participants with advanced or metastatic muscle invasive bladder cancer

It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).

1 finding from 1 review

Immune checkpoint inhibitors vs any second‐line chemotherapy

Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).

1 finding from 1 review

Immune checkpoint inhibitors vs any first‐line chemotherapy

Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).

1 finding from 1 review